188 related articles for article (PubMed ID: 22824225)
1. How pragmatic or explanatory is the randomized, controlled trial? The application and enhancement of the PRECIS tool to the evaluation of a smoking cessation trial.
Selby P; Brosky G; Oh PI; Raymond V; Ranger S
BMC Med Res Methodol; 2012 Jul; 12():101. PubMed ID: 22824225
[TBL] [Abstract][Full Text] [Related]
2. Do randomized controlled nursing trials have a pragmatic or explanatory attitude? Findings from the Pragmatic-Explanatory Continuum Indicator Summary (PRECIS) tool exercise.
Palese A; Bevilacqua MG; Dante A;
J Nurs Res; 2014 Sep; 22(3):216-20. PubMed ID: 25111115
[TBL] [Abstract][Full Text] [Related]
3. A dynamic application of PRECIS-2 to evaluate implementation in a pragmatic, cluster randomized clinical trial in two nursing home systems.
Palmer JA; Mor V; Volandes AE; McCreedy E; Loomer L; Carter P; Dvorchak F; Mitchell SL
Trials; 2018 Aug; 19(1):453. PubMed ID: 30134976
[TBL] [Abstract][Full Text] [Related]
4. An application of PRECIS-2 to evaluate trial design in a pilot cluster randomised controlled trial of a community-based smoking cessation intervention for women living in disadvantaged areas of Ireland.
Darker C; Loudon K; O'Connell N; Castello S; Burke E; Vance J; Reynolds C; Buggy A; Dougall N; Williams P; Dobbie F; Bauld L; Hayes CB
Pilot Feasibility Stud; 2022 Jan; 8(1):19. PubMed ID: 35078530
[TBL] [Abstract][Full Text] [Related]
5. A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers.
Thorpe KE; Zwarenstein M; Oxman AD; Treweek S; Furberg CD; Altman DG; Tunis S; Bergel E; Harvey I; Magid DJ; Chalkidou K
J Clin Epidemiol; 2009 May; 62(5):464-75. PubMed ID: 19348971
[TBL] [Abstract][Full Text] [Related]
6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
7. [The PRECIS-2 tool: designing trials that are fit for purpose].
Hu GP; Zhan SY
Zhonghua Liu Xing Bing Xue Za Zhi; 2018 Feb; 39(2):222-226. PubMed ID: 29495210
[TBL] [Abstract][Full Text] [Related]
8. Making clinical trials more relevant: improving and validating the PRECIS tool for matching trial design decisions to trial purpose.
Loudon K; Zwarenstein M; Sullivan F; Donnan P; Treweek S
Trials; 2013 Apr; 14():115. PubMed ID: 23782862
[TBL] [Abstract][Full Text] [Related]
9. Systematic Review of the "Pragmatism" of Pragmatic Critical Care Trials.
Palakshappa JA; Gibbs KW; Lannan MT; Cranford AR; Taylor SP
Crit Care Explor; 2022 Jul; 4(7):e0738. PubMed ID: 35923590
[TBL] [Abstract][Full Text] [Related]
10. Designing provider-focused implementation trials with purpose and intent: introducing the PRECIS-2-PS tool.
Norton WE; Loudon K; Chambers DA; Zwarenstein M
Implement Sci; 2021 Jan; 16(1):7. PubMed ID: 33413489
[TBL] [Abstract][Full Text] [Related]
11. The PRECIS-2 tool seems not to be useful to discriminate the degree of pragmatism of medicine masked trials from that of open-label trials.
Dal-Ré R
Eur J Clin Pharmacol; 2021 Apr; 77(4):539-546. PubMed ID: 33106910
[TBL] [Abstract][Full Text] [Related]
12. Facing the Realities of Pragmatic Design Choices in Environmental Health Studies: Experiences from the Household Air Pollution Intervention Network Trial.
Checkley W; Hossen S; Rosa G; Thompson LM; McCracken JP; Diaz-Artiga A; Balakrishnan K; Simkovich SM; Underhill LJ; Nicolaou L; Hartinger SM; Davila-Roman VG; Kirby MA; Clasen TF; Rosenthal J; Peel JL; On Behalf Of Household Air Pollution Intervention Network Hapin Investigators
Int J Environ Res Public Health; 2022 Mar; 19(7):. PubMed ID: 35409475
[TBL] [Abstract][Full Text] [Related]
13. Real-world evidence: How pragmatic are randomized controlled trials labeled as pragmatic?
Dal-Ré R; Janiaud P; Ioannidis JPA
BMC Med; 2018 Apr; 16(1):49. PubMed ID: 29615035
[TBL] [Abstract][Full Text] [Related]
14. Framing the conversation: use of PRECIS-2 ratings to advance understanding of pragmatic trial design domains.
Lipman PD; Loudon K; Dluzak L; Moloney R; Messner D; Stoney CM
Trials; 2017 Nov; 18(1):532. PubMed ID: 29126437
[TBL] [Abstract][Full Text] [Related]
15. Generalizability of randomized controlled trials in primary health care: Applying the PRECIS-2 tool on published protocols.
Papagiannopoulou E; Laiou E; Tatsi C; Dimakopoulos G; Ntzani EE; Siamopoulos K; Tatsioni A
J Eval Clin Pract; 2023 Mar; 29(2):253-262. PubMed ID: 36072984
[TBL] [Abstract][Full Text] [Related]
16. Use of PRECIS ratings in the National Institutes of Health (NIH) Health Care Systems Research Collaboratory.
Johnson KE; Neta G; Dember LM; Coronado GD; Suls J; Chambers DA; Rundell S; Smith DH; Liu B; Taplin S; Stoney CM; Farrell MM; Glasgow RE
Trials; 2016 Jan; 17():32. PubMed ID: 26772801
[TBL] [Abstract][Full Text] [Related]
17. Integrating pragmatic and implementation science randomized clinical trial approaches: a PRagmatic Explanatory Continuum Indicator Summary-2 (PRECIS-2) analysis.
Zatzick D; Palinkas L; Chambers DA; Whiteside L; Moloney K; Engstrom A; Prater L; Russo J; Wang J; Abu K; Iles-Shih M; Bulger E
Trials; 2023 Apr; 24(1):288. PubMed ID: 37085877
[TBL] [Abstract][Full Text] [Related]
18. The PRECIS-2 tool has good interrater reliability and modest discriminant validity.
Loudon K; Zwarenstein M; Sullivan FM; Donnan PT; Gágyor I; Hobbelen HJSM; Althabe F; Krishnan JA; Treweek S
J Clin Epidemiol; 2017 Aug; 88():113-121. PubMed ID: 28603007
[TBL] [Abstract][Full Text] [Related]
19. How pragmatic are randomized trials of remdesivir and favipiravir for in-hospital treatment of COVID-19: a descriptive methodological review of trial design using the PRECIS-2 framework.
Sharma T; Qamar I; Zwarenstein M
J Clin Epidemiol; 2022 Dec; 152():193-200. PubMed ID: 36265553
[TBL] [Abstract][Full Text] [Related]
20. The value of the pragmatic-explanatory continuum indicator summary wheel in an ongoing study: the bullous pemphigoid steroids and tetracyclines study.
Bratton DJ; Nunn AJ; Wojnarowska F; Kirtschig G; Sandell A; Williams HC
Trials; 2012 Apr; 13():50. PubMed ID: 22540678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
